Nautilus Biotechnology analyst ratings
Nautilus Biotechnology analyst ratings
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a maintained with a price target of $4.00 to $2.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.82, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2022 | -29.08% | Goldman Sachs | $4 → $2 | Maintains | Neutral |
| 07/14/2022 | 41.84% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 04/13/2022 | 77.3% | Goldman Sachs | $9 → $5 | Maintains | Neutral |
| 01/06/2022 | 183.69% | Morgan Stanley | → $8 | Initiates Coverage On | → Equal-Weight |
| 11/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/04/2021 | 254.61% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/13/2021 | 360.99% | Jefferies | → $13 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/03/2022 | -29.08% | 高盛 | $4→$2 | 維護 | 中性 |
| 07/14/2022 | 41.84% | 高盛 | $5→$4 | 維護 | 中性 |
| 04/13/2022 | 77.3% | 高盛 | $9→$5 | 維護 | 中性 |
| 01/06/2022 | 183.69% | 摩根士丹利 | →$8 | 開始承保 | →等重 |
| 11/02/2021 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 08/04/2021 | 254.61% | 高盛 | →$10 | 開始承保 | →中性 |
| 07/13/2021 | 360.99% | 傑富瑞 | →$13 | 開始承保 | →購買 |
Nautilus Biotechnology Questions & Answers
鸚鵡螺生物技術問答
The latest price target for Nautilus Biotechnology (NASDAQ: NAUT) was reported by Goldman Sachs on August 3, 2022. The analyst firm set a price target for $2.00 expecting NAUT to fall to within 12 months (a possible -29.08% downside). 6 analyst firms have reported ratings in the last year.
高盛於2022年8月3日報道了鸚鵡螺生物科技公司(納斯達克：NAUT)的最新目標價。這家分析公司將目標價定為2.00美元，預計NOUT將在12個月內下跌(可能下跌29.08%)。6家分析公司在過去一年公佈了評級。
The latest analyst rating for Nautilus Biotechnology (NASDAQ: NAUT) was provided by Goldman Sachs, and Nautilus Biotechnology maintained their neutral rating.
納斯達克股票代碼：NAUT的最新分析師評級由高盛提供，鸚鵡螺生物科技維持中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與鸚鵡螺生物科技公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對鸚鵡螺生物技術的上一次評級是在2022年8月3日提交的，所以你應該預計下一次評級將在2023年8月3日左右的某個時候公佈。
While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a maintained with a price target of $4.00 to $2.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.82, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的鸚鵡螺生物技術(Naut)評級維持不變，目標價在4.00美元至2.00美元之間。鸚鵡螺生物技術公司(Nautilus Biotech)目前的股價為2.82美元，超出了分析師的預測區間。